Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Obstet Gynecol. 2010 Jul;203(1):52.e1-6. doi: 10.1016/j.ajog.2010.02.015. Epub 2010 Apr 24.

Maternal use of bupropion and risk for congenital heart defects.

Author information

  • 1Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

Abstract

OBJECTIVE:

We sought to determine if maternal bupropion treatment in early pregnancy is associated with congenital heart defects in the infant.

STUDY DESIGN:

We conducted a retrospective case-control study of birth defects risk factors. Data on 6853 infants with major heart defects were compared with 5869 control infants born in 1997-2004. Bupropion exposure was defined as any reported use between 1 month before and 3 months after conception.

RESULTS:

Mothers of infants with left outflow tract heart defects were more likely to have reported taking bupropion than mothers of control infants (adjusted odds ratio, 2.6; 95% confidence interval, 1.2-5.7; P = .01).

CONCLUSION:

We identified a positive association between early pregnancy bupropion use and left outflow tract heart defects; however, the magnitude of the observed increased risk was small. Nevertheless, further studies are needed to confirm these results.

Copyright (c) 2010 Mosby, Inc. All rights reserved.

PMID:
20417496
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk